《大行報告》花旗首予新秀麗(01910.HK)「買入」評級 目標價32元
花旗發表報告指,首予新秀麗(01910.HK)投資評級爲「買入」,以及其目標價爲32元,相當於預測明年市盈率16倍。
該行表示,隨着全球重新開放,新秀麗旗下業務恢復進度不俗,包括市場份額增長良好、以及利潤率創歷史新高。隨着亞洲,尤其是中國經濟重開,加快其復甦步伐,而北美或歐洲仍會繼續增長,料公司應會回覆至超越疫前水平。
花旗預料新秀麗股票將會繼續重估,主要是業績表現持續穩健,亦令該行在新秀麗發佈中期業績前,保持30日正面催化劑觀察。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.